Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A GLOBAL CONGRESS DIGEST ON LUNG CANCER

A GLOBAL CONGRESS DIGEST ON LUNG CANCER special issue ESMO 2016 ESMO 2016 Table of Contents 72 Preface 72 Immune checkpoint inhibition: the picture is slowly completing itself 76 Next-generation ALK inhibitors excel after crizotinib failure 78 Interview: “Targeting angiogenesis can prolong life” 80 EGFR-targeted therapy: at the right time in the right patient 83 Rare driver mutations: encouraging results in small patient populations 85 SCLC: genomic alterations pave the way to targeted approaches 87 No phase III benefit with selumetinib in KRAS-mutant NSCLC Editorial Board: Alex A. Adjei, MD, PhD, FACP, Roswell Park, Cancer Institute, New York, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan, Italy Barbara Melosky, MD, FRCPC, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada Nir Peled, MD, PhD, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png memo - Magazine of European Medical Oncology Springer Journals

A GLOBAL CONGRESS DIGEST ON LUNG CANCER

memo - Magazine of European Medical Oncology , Volume 9 (4) – Dec 14, 2016

Loading next page...
 
/lp/springer-journals/a-global-congress-digest-on-lung-cancer-rpcU8RreI0
Publisher
Springer Journals
Copyright
Copyright © 2016 by Springer-Verlag Wien
Subject
Medicine & Public Health; Oncology; Medicine/Public Health, general
ISSN
1865-5041
eISSN
1865-5076
DOI
10.1007/s12254-016-0306-0
Publisher site
See Article on Publisher Site

Abstract

special issue ESMO 2016 ESMO 2016 Table of Contents 72 Preface 72 Immune checkpoint inhibition: the picture is slowly completing itself 76 Next-generation ALK inhibitors excel after crizotinib failure 78 Interview: “Targeting angiogenesis can prolong life” 80 EGFR-targeted therapy: at the right time in the right patient 83 Rare driver mutations: encouraging results in small patient populations 85 SCLC: genomic alterations pave the way to targeted approaches 87 No phase III benefit with selumetinib in KRAS-mutant NSCLC Editorial Board: Alex A. Adjei, MD, PhD, FACP, Roswell Park, Cancer Institute, New York, USA Maria Rosario Garcia Campelo, MD, Lung Cancer and Thoracic Tumors, University Hospital Quirón A Coruña, La Coruña, Spain Federico Cappuzzo, MD, Medical Oncology Department, Ospedale Civile di Livorno, Livorno, Italy Wolfgang Hilbe, MD, Departement of Oncology, Hematology and Palliative Care, Wilhelminenspital, Vienna, Austria Maximilian Hochmair, MD, 1. Interne Lungenabteilung, Otto-Wagner-Spital, Vienna, Austria Massimo Di Maio, MD, National Institute of Tumor Research and Therapy, Foundation G. Pascale, Napoli, Italy Filippo de Marinis, MD, PhD, Director of the Thoracic Oncology Division at the European Institute of Oncology (IEO), Milan, Italy Barbara Melosky, MD, FRCPC, University of British Columbia and British Columbia Cancer Agency, Vancouver, Canada Nir Peled, MD, PhD,

Journal

memo - Magazine of European Medical OncologySpringer Journals

Published: Dec 14, 2016

There are no references for this article.